Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR …
Jan 8, 2025 · CRANFORD, NJ, USA I January 7, 2025 I Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell ...
RiDYMO® Designs Cyclic Peptide for "Undruggable" β-Catenin …
Jan 9, 2025 · BEIJING, China I January 8, 2025 I In a recent achievement, DP Technology’s hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting β-catenin, a historically “undruggable” protein, in just two months. This innovative AI-driven approach combines advanced algorithms, physics simulations, and high-throughput experimentation to rapidly develop potential drug ...
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's …
Jan 16, 2025 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
miRecule and GBI Biomanufacturing Announce Strategic …
Jan 28, 2025 · PLANTATION, FL, and GAITHERSBURG, MD, USA I January 28, 2025 I miRecule, a biotechnology company pioneering RNA therapies, and GBI Biomanufacturing, a leading contract development and manufacturing organization (CDMO), today announced a strategic partnership to advance the development and clinical supply of miRecule’s innovative Antibody-RNA Conjugate (ARC) based products.
Keylicon Biosciences Secures Exclusive Rights to Modified Self ...
Jan 14, 2025 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free ...
Jan 11, 2025 · NEW YORK, NY. USA I January 10, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin (BCG) as induction therapy with or ...
Leyden Labs Raises $70M to Advance its Intranasal Antibody …
Jan 9, 2025 · Funding will propel Leyden Labs’ non-vaccine intranasal antibody programs to safeguard people from respiratory viruses. The programs are based on Leyden Labs’ Mucosal Protection Platform utilizing broadly protective antibodies. Round led by ClavystBio (a life sciences venture investor ...
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a …
Jan 31, 2025 · — JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years — — JOURNAVX is an effective and well-tolerated medicine without evidence of addictive potential indicated for use across all types of ...
Immusoft to Present Positive Data from the First Engineered B Cell …
Jan 28, 2025 · Poster Presentation: Wednesday, February 5 th, 2026, 3:30-5:30 PM PST, Kiosk 27-B. Title: Safety and initial activity of autologous human B cells genetically engineered to express human iduronidase using the Sleeping Beauty transposon system: Results from a first-in-human clinical trial in subjects ...
etherna Announces Strategic Multi-Target Collaboration with …
Jan 9, 2025 · NIEL, Belgium and BOSTON, MA, USA I January 9, 2025 I etherna immunotherapies NV (“etherna”), a technology platform leader pioneering mRNA and lipid-based nanoparticle (LNP) technologies, announces a strategic collaboration with Dropshot Therapeutics (“Dropshot”). The collaboration combines the cutting-edge platforms of both companies to accelerate the development of RNA-based ...